HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Zydus Lifesciences Ltd Stock Comparison

Cohance Lifesciences Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: Jul 24, 2025

Key Highlights

  • The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 1045 as of 24 Jul 10:58.
  • The P/E Ratio of Cohance Lifesciences Ltd changed from 8.1 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 19.7 on March 2025 . This represents a CAGR of -2.76% over 6 years.
  • The Market Cap of Cohance Lifesciences Ltd changed from ₹ 2564 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 89122 crore on March 2025 . This represents a CAGR of 21.76% over 6 years.
  • The revenue of Cohance Lifesciences Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79% The revenue of Zydus Lifesciences Ltd for the Mar '25 is ₹ 6608 crore as compare to the Dec '24 revenue of ₹ 5326 crore. This represent the growth of 24.07%.
  • The ebitda of Cohance Lifesciences Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94% The ebitda of Zydus Lifesciences Ltd for the Mar '25 is ₹ 1986 crore as compare to the Dec '24 ebitda of ₹ 1444 crore. This represent the growth of 37.49%.
  • The net profit of Cohance Lifesciences Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1248 crore over 8 quarters. This represents a CAGR of 5.97% .
  • The Dividend Payout of Cohance Lifesciences Ltd changed from 23.57 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 19.16 % on March 2025 . This represents a CAGR of -4.57% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Cohance Lifesciences Ltd News Hub

News

Cohance Lifesciences to announce Quarterly Result

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 13 Au...

Read more

28 Jun 2025 09:56

News

Cohance Lifesciences to hold AGM

Cohance Lifesciences announced that the 7th Annual General Meeting(AGM) of the company wil...

Read more

27 Jun 2025 15:41

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

Zydus Lifesciences Ltd News Hub

News

Zydus' Matoda facility completes Remote Regulatory Assessment of USFDA

Zydus Lifesciences announced that the USFDA conducted a Remote Regulatory Assessment (RRA)...

Read more

16 Jul 2025 17:55

News

Zydus Lifesciences gets USFDA Nod for Celecoxib Capsules

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones ...

Read more

15 Jul 2025 15:45

News

Zydus Life Matoda facility receives two observations from USFDA after inspection

In a regulatory filing, the company confirmed that the USFDA conducted a follow-up inspect...

Read more

19 Jun 2025 09:50

News

Zydus Lifesciences appoints Managing Director

Zydus Lifesciences has approved the appointment of s. Swati Dalal as the Additional Direct...

Read more

16 Jun 2025 14:16

News

Zydus Life subsidiary ZHL appoints Swati Dalal as MD

The appointment was approved by the nomination and remuneration committee (NRC). Swati Dal...

Read more

16 Jun 2025 14:42

News

Zydus Life receives USFDA EIR for Gujarat facility

The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the r...

Read more

12 Jun 2025 09:55

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

SWOT Analysis Of Cohance Lifesciences Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cohance Lifesciences Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Zydus Lifesciences Ltd?

Market cap of Cohance Lifesciences Ltd is 39,995 Cr while Market cap of Zydus Lifesciences Ltd is 96,824 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Zydus Lifesciences Ltd?

The stock performance of Cohance Lifesciences Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Zydus Lifesciences Ltd?

As of July 24, 2025, the Cohance Lifesciences Ltd stock price is INR ₹1045.45. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹962.25.

How do dividend payouts of Cohance Lifesciences Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions